Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001074986 | SCV001240595 | pathogenic | Retinal dystrophy | 2017-11-13 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002554734 | SCV003524200 | pathogenic | not provided | 2022-08-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gly570Glufs*3) in the PCARE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PCARE are known to be pathogenic (PMID: 20398886, 24339724, 26496393). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with retinitis pigmentosa (PMID: 27353947). ClinVar contains an entry for this variant (Variation ID: 866727). For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV001074986 | SCV005072346 | pathogenic | Retinal dystrophy | 2018-01-01 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004753204 | SCV005361430 | pathogenic | PCARE-related disorder | 2024-09-03 | no assertion criteria provided | clinical testing | The PCARE c.1709_1728del20 variant is predicted to result in a frameshift and premature protein termination (p.Gly570Glufs*3). This variant has been reported homozygous and compound heterozygous with other PCARE loss-of-function variants in multiple individuals with retinitis pigmentosa (Table 1, Tiwari et al. 2016. PubMed ID: 27353947; Table 1, Gerth-Kahlert et al. 2017. PubMed ID: 28763557). This variant is reported in one allele out of ~249,000 alleles in gnomAD. Frameshift variants in PCARE are expected to be pathogenic. This variant is interpreted as pathogenic. |